Share Twitter LinkedIn Facebook Email David Braun, MD, PhD DF/HCC Kidney Cancer SPORE Harvard Medical School discusses Understanding CD8+ T Cell Function and Specificity in RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL.
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
